Cargando…

Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases

We reviewed the available information on the use of immune checkpoint inhibitors (ICIs) in populations with special conditions, namely, patients with HIV, tuberculosis, or underlying autoimmune disease. Available data show that treatment with ICIs is safe in patients with HIV; it is advisable, howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguilar-Company, Juan, Lopez-Olivo, Maria A., Ruiz-Camps, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334667/ https://www.ncbi.nlm.nih.gov/pubmed/35911382 http://dx.doi.org/10.3389/fmed.2022.875910

Ejemplares similares

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
por: Coureau, Michelle, et al.
Publicado: (2020)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Top-ten infections in onco-hematological patients (2015-2017)
por: Camps, Isabel Ruiz, et al.
Publicado: (2019)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
por: Cardeña-Gutiérrez, Ana, et al.
Publicado: (2022)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
por: Iranzo, Patricia, et al.
Publicado: (2022)

Integration of Next-generation Sequencing and Immune Checkpoint Inhibitors in Targeted Symptom Control and Palliative Care in Solid Tumor Malignancies: A Multidisciplinary Clinician Perspective
por: Feinsilber, Doron, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review
por: Ruiz, Juan I., et al.
Publicado: (2023)

Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
por: Moss, Emily M., et al.
Publicado: (2022)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study
por: Lopez-Olivo, Maria A., et al.
Publicado: (2023)

Quality and content evaluation of websites with information about immune checkpoint inhibitors: An environmental scan
por: Ruiz, Juan Ignacio, et al.
Publicado: (2022)

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
por: Dietz, Hilary, et al.
Publicado: (2021)

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma
por: Lee, Ahlim, et al.
Publicado: (2022)

Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

Isolated Neutropenia Due to Immune Checkpoint Inhibitors
por: Jalil, Ahmad, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors
por: Patel, Priyanka, et al.
Publicado: (2021)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

A Case of Immune Checkpoint Inhibitor Induced Autoimmune Diabetes
por: Thambuluru, Sirisha Reddy
Publicado: (2021)

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
por: Duong, Sophie L., et al.
Publicado: (2022)

Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
por: Maeda, Osamu
Publicado: (2023)

Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas
por: Salinas, Nadia, et al.
Publicado: (2021)

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study
por: Shieh, Kevin R., et al.
Publicado: (2021)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Seronegative Rheumatoid Arthritis Secondary to Immune Checkpoint Inhibitor in a Renal Cell Carcinoma Patient Encountered in a Rural Community-Based Rheumatology Clinic: A Case Report
por: De Camps Martinez, Elmer R, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
por: Inno, Alessandro, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
por: Chen, Ru, et al.
Publicado: (2021)

Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
por: Zhang, Xin, et al.
Publicado: (2023)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity
por: Tampe, Désirée, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tmn11scfrkq4q04tobe4slldap